Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 7.4% – Should You Buy?

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) shot up 7.4% during mid-day trading on Friday . The stock traded as high as $26.92 and last traded at $27.0350. 388,599 shares were traded during mid-day trading, a decline of 81% from the average session volume of 2,057,477 shares. The stock had previously closed at $25.17.

Analyst Upgrades and Downgrades

ELVN has been the subject of several analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, October 8th. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.00.

Enliven Therapeutics Trading Up 7.4%

The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of -14.69 and a beta of 0.41. The stock’s 50-day moving average is $19.60 and its 200-day moving average is $20.09.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. On average, equities research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Insider Buying and Selling at Enliven Therapeutics

In related news, COO Anish Patel sold 48,300 shares of the business’s stock in a transaction on Friday, January 9th. The shares were sold at an average price of $27.99, for a total value of $1,351,917.00. Following the sale, the chief operating officer owned 215,011 shares of the company’s stock, valued at $6,018,157.89. The trade was a 18.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Richard A. Heyman sold 4,285 shares of the firm’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $25.00, for a total value of $107,125.00. Following the transaction, the director directly owned 25,107 shares of the company’s stock, valued at approximately $627,675. This represents a 14.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 250,550 shares of company stock valued at $6,344,066 in the last quarter. 25.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Enliven Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. lifted its position in shares of Enliven Therapeutics by 61.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock worth $4,167,000 after purchasing an additional 80,506 shares during the period. Affinity Asset Advisors LLC bought a new position in Enliven Therapeutics during the second quarter worth $8,024,000. Geode Capital Management LLC raised its stake in Enliven Therapeutics by 7.8% during the second quarter. Geode Capital Management LLC now owns 882,753 shares of the company’s stock worth $17,711,000 after buying an additional 63,580 shares during the last quarter. Franklin Resources Inc. lifted its holdings in Enliven Therapeutics by 2,029.3% in the second quarter. Franklin Resources Inc. now owns 430,240 shares of the company’s stock valued at $8,631,000 after buying an additional 410,034 shares during the period. Finally, KLP Kapitalforvaltning AS boosted its position in Enliven Therapeutics by 58.1% during the second quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock valued at $136,000 after acquiring an additional 2,500 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.